In this article, Sino Biological discusses targeting myeloid-derived suppressor cells in the tumor microenvironment to improve the efficacy of tumor immunotherapy.
Sino Biological produces a huge range of reagents and therapeutic targets for neurodegenerative diseases, helping combat the rise in Alzheimer’s and Parkinson’s Disease.
Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.